PRS55 - COST-EFFECTIVENESS OF MEPOLIZUMAB IN SEVERE EOSINOPHILIC ASTHMA PATIENTS IN FRANCE.
F. Maunoury1, C. Pribil2, M. Aubier3, G. Nachbaur2, S. Doyle4
1 STATESIA, Le Mans, France; 2 GlaxoSmithKline, RueilMalmaison, France; 3 Bichat University Hospital, Paris, France; 4 GlaxoSmithKline, London, UK
COST-EFFECTIVENESS OF ELBASVIR-GRAZOPREVIR ASSOCIATION FOR TREATING HEPATITIS C VIRUS GENOTYPE 1 INFECTION IN STAGE 4-5 CHRONIC KIDNEY DISEASE PATIENTS IN FRANCE.
Maunoury F1, Duguet A2, Elbasha E3, Abergel A4, Di Martino V5, Thervet E6, Levy-Bachelot L2, Durand-Zaleski I7
1Statesia, Le Mans, France; 2 MSD FRANCE, Courbevoie, France; 3 MRL, Merck & Co., Inc., North Wales, PA USA; 4PU-PH, Hepato-gastro enterology Service, CHU Estaing, Clermont-Ferrand, France; 5PU-PH, Hepatology department head, Franche-Comté University and Besançon University hospital, Besançon, France; 6MD, PhD, HYPPARC Department, Nephrology Service, Paris Descartes University & Georges Pompidou European Hospital, Paris, France; 7PU-PH, Director of the Ile-De-France URC ECO, Head of Service of Public Health Health Economics, Henri Mondor Hospital, Créteil, France
COST-EFFECTIVENESS MODELING OF ANTIMICROBIAL DRESSINGS FOR PREVENTING CATHETER-RELATED BLOODSTREAM INFECTION: HOMOGENEOUS VERSUS NON-HOMOGENEOUS MARKOV APPROACHES
Maunoury F1, Motrunich A1, Palka-Santini M2
1Statésia, Le Mans, France, 23M Germany, Neuss, Germany
COST-EFFECTIVENESS ANALYSIS OF AN ANTIMICROBIAL TRANSPARENT DRESSING FOR PROTECTING CENTRAL VASCULAR ACCESSES IN CRITICALLY ILL PATIENTS VERSUS STANDARD TRANSPARENT DRESSINGS IN FRANCE: A COMPARISON OF TWO MODELING APPROACHES: DECISION-TREE VERSUS NON-HOMOGENEOUS MARKOV MODEL
Palka-Santini M1, Motrunich A2, Maunoury F2
13M Germany, Neuss, Germany, 2Statésia, Le Mans, France
Non-Homogeneous Cost-Effectiveness Modeling of a new CHG-Dressing for preventing Catheter-related Bloodstream Infections for Patients in Intensive Care Units
Maunoury F1, Motrunich A1, Ruckly S2, Timsit JF2. 1Statésia, Le Mans, Paris, France; 2Grenoble University Hospital, Grenoble, France
Cost evaluation of topical therapies for patients with psoriasis in France
F. Maunoury1,* B. Halioua2 A. Motrunich1, A. Maury Le Breton3, A.De Fontaubert3, F. Dogniaux3 M.-E. Roussel3 J.-F. Stalder4. 1Statésia, Le Mans, Paris, France;2Dermatology, Institut Alfred Fournier, Paris, France; 3LEO Pharma France,Voisins-Le-Bretonneux, France; 4Head of the Department of Dermatology, Nantes University Hospital, Nantes, France
Prevalence and characteristics of cyber psoriatic patients
B. Halioua,1,* A. Motrunich,2 A. MauryLe Breton,3 A.De Fontaubert,3 F. Maunoury,2 M.-E. Roussel,3 F. Dogniaux,3 J.-F. Stalder4 1Dermatology, Institut Alfred Fournier, Paris; 2Statésia, Le Mans, France; 3LEO Pharma France, Voisins-Le-Bretonneux, France; 4Dermatology, Nantes University Hospital, Nantes, France
Prevalence and characteristics of psoriatic patients reporting feeling of Stigmatization
B. Halioua1,* A. Motrunich2, A. Maury Le Breton3, A.De Fontaubert3, F. Maunoury2, M.-E. Roussel3, F. Dogniaux3, J.-F. Stalder4. 1Dermatology, Institut Alfred Fournier, Paris, France; 2Statésia, Le Mans, France; 3LEO Pharma France, Voisins-Le-Bretonneux, France; 4Dermatology, CHU Nantes, Nantes, France
Risk factors of sexual dysfunction in patients with psoriasis
B. Halioua,1,* A. Motrunich,2 A. MauryLe Breton,3 A.De Fontaubert,3 F. Maunoury,2 M.-E. Roussel,3 F. Dogniaux,3 J.-F. Stalder4 1Dermatology, Institut Alfred Fournier, Paris; 2Statistician-Health economist, Statésia, Le Mans, France; 3Leo Pharma France, Voisins-Le-Bretonneux, France; 4Dermatology, Nantes University Hospital, Nantes, France
Insomnia in patients with psoriasis: consequences and associated factors
B. Halioua,1,* A. Motrunich,2 A. MauryLe Breton,3 A.De Fontaubert,3 F. Maunoury,2 M.-E. Roussel,3 F. Dogniaux, 3 J.-F. Stalder4 1Dermatology, Institut Alfred Fournier, Paris, France; 2Statésia, Le Mans, France; 3LEO Pharma France, Voisins-Le- Bretonneux, France; 4Dermatology, CHU Nantes, Nantes, France
Prevalence of negative feelings and misconceptions about psoriasis in French population
B. Halioua,1,* A. Motrunich,2 A. MauryLe Breton,3 A.De Fontaubert,3 F. Maunoury,2 M.-E. Roussel,3 F. Dogniaux,3 J.-F. Stalder4 1Dermatology, Institut Alfred Fournier, Paris, France; 2Statésia, Le Mans, France; 3LEO Pharma France, Voisins-Le-Bretonneux, France; 4Dermatology, Nantes University Hospital, Nantes, France
ISPOR 15th Annual European Congress, International Society for Pharmacoeconomics and Outcomes Research, Berlin. Challenging Times for Health Care Decisions in Europe: Changing Models of HTA, Price Referencing & Integrating Social Preferences. November, 2012.
Cost-Effectiveness of the TLC-NOSF Dressing in venous leg ulcer
Maunoury F1, Motrunich A1, Fortin S2. 1Statésia, Le Mans, France, 2Laboratoires URGO, Chenôve, France.
ISPOR 12th European Congress, International Society for Pharmacoeconomics and Outcomes Research – Paris - Health Care Decision Making in Europe: From Patients to Populations. November, 2009.
Can the french gatekeeping system be cost-effective for patients with chronic respiratory disorder?
Maunoury F1-2, VanHille JL3, Véron N3, Bounekkar A1, Fantino B4, Auray JP1, Launois R5 1Claude Bernard University Lyon 1, Villeurbanne, France, 2Statésia, Le Mans, France, 3Regional Health Insurance Medical Service, Orléans, France, 4ADIM -AGORAS, Lyon, France, 5REES France, Paris, France
French gatekeeping cost-effectiveness impact on chronic patients treated with inhaled corticosteroids, in real life
Maunoury F1-2, VanHille JL3, Véron N3, Bounekkar A1, Fantino B4, Auray JP1, Launois R5 1Claude Bernard University Lyon 1, Villeurbanne, France, 2Statésia, Le Mans, France, 3Regional Health Insurance Medical Service, Orléans, France, 4ADIM -AGORAS, Lyon, France, 5REES France, Paris, France
Mixed treatment comparisons: an evidence-based budget impact model of Rituximab (Mabthera®) after failure of one or more TNF inhibitor therapies in the treatment of rheumatoid arthritis
Launois R1, Riou-Franca L1, Maunoury F3 ,BoissierMC2, Florentin V4 1REES France, Paris, France, 2Université Paris Nord, Hôpital Avicenne, AP-HP, Paris, France, 3Statésia, Le Mans, France, 4Roche, Neuilly sur Seine, France
9th International conference on system science in health care, September 2008.
The Markovian Decision Process: Adaptation of "msm" algorithms for medicoeconomic assessment studies.
F. Maunoury, A. Bounekkar, S. Bonnevay, JP Auray LIRIS UMR CNRS 5205, Research Team MA²D, Claude Bernard University of Lyon1, 2008.